CPC A61K 38/26 (2013.01) [A61K 31/155 (2013.01); A61K 31/5415 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); C07K 14/605 (2013.01); C07K 16/082 (2013.01); C07K 16/2869 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)] | 5 Claims |
1. A method of lowering blood sugar level in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a fusion protein consisting of a glucagon-like peptide 1 (GLP1) variant and a stabilizing domain, and wherein: (i) the GLP1 variant consists of SEQ ID NO: 6; (ii) the stabilizing domain is an antibody or antigen-binding fragment thereof that binds specifically to GLP1 receptor; and (iii) the fusion protein has enhanced resistance to proteolytic cleavage and/or enhanced blood glucose lowering ability.
|